Company intelligence / Profile preview

SunAct Cancer Institute

Mumbai, Maharashtra, India

Ownership: Private
Development stage: Other

Overview

SunAct Cancer Institute is conducting a Phase 2 clinical trial (jointly with CytoMed Therapeutics) evaluating allogeneic gamma delta T cell therapy for solid tumors and other cancers. Preliminary results include India’s first successful use of allogeneic CAR-T for solid tumors; further trials underway with focus on safety, tolerability, and efficacy, though no published clinical trial outcomes are yet available.

Therapeutic areas: HematologyOncology
Modalities: CAR-T cell therapyGene therapyCRISPR-based therapyImmunotherapyStem cell therapyBone marrow transplantT cell receptor engineered T cell therapyGamma delta T cell therapy
Industry: Academic Hospital/University/Research

Partnerships

Smita Memorial Hospital & Research CentreCytoMed Therapeutics

Beyond the preview

Go deeper on SunAct Cancer Institute.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SunAct Cancer Institute.

Explore the full profile